Lung

Question 1

Limited stage sclc cure rate

Answer 1

20%

Question 2

Limited stage sclc treatment

Answer 2

Cispetop 3d with rads
C 60 x 1 e 120 x 3
C75 x 1 e 100 x 3
C25 e 100 x 3

Question 3

Nsclc kras mutations in adenocarcinoma are exclusive to

Answer 3

Smokers

Question 4

Kras frequency in nsclc

Answer 4

10 - 30 %

Question 5

Egfr frequency in nsclc

Answer 5

10 - 15%

Question 6

Mutation causing 50 - 60% of the resistance to egfr tki is

Answer 6

T790M

Question 7

T790M causes resistance to

Answer 7

Erlotinib, gefitinib and afatinib

Question 8

What cycle should rads begin with limited stage sclc

Answer 8

Early. Cycle 1 or 2

Question 9

Prophylaxis cranial irradiation should be offered to all pt with cr or pr (LS sclc) except

Answer 9

Pt over 60 risk vs benefit of cognitive decline and pt with poor performance status or baseline impaired cognitive function

Question 10

Which platinum is better for ES sclc

Answer 10

Carbo and cisp are equal

Question 11

Platinum is combined with ____ or_____ in ES nsclc

Answer 11

Etoposide or irinotecan

Question 12

IO approved for ED sclc

Answer 12

Durvalumab and atezolizumab

Question 13

Treatment for ES sclc

Answer 13

Platinum doublet with IO followed by maintenance IO

Question 14

Timing of platinum sensitive, relapse and refractory for ES sclc

Answer 14

Ps > 6 months
Relapse > 3 months
Refractory < 3 months

Question 15

EML4-ALK frequency in nsclc

Answer 15

4-8%

Question 16

ROS1 rearrangement nsclc frequency

Answer 16

1-2%

Question 17

Cancer positive for EGFR, ALK or ROS1 is usually negative for

Answer 17

PD-L1 tumor expression

Question 18

T or F gcsf should be used maintain dose intensity in sclc

Answer 18

False

Question 19

What stages of nsclc are surgically resectable

Answer 19

1 2 and 3A

Question 20

Adjuvant radiation is best for nsclc when

Answer 20

Stage 1 or 2 positive margins or stage 3A

Question 21

Stage of nsclc adjuvant chemo recommended and type

Answer 21

Stage 2 A and B and 3A. Cisplatin based

Question 22

Nsclc stage 3B treatment recommendation

Answer 22

Concurrent chemo and rads. Hope to downstage

Question 23

Post concurrent chemorads in unresectable stage 3 nsclc

Answer 23

Durvalumab x 12 months

Question 24

What subset of pts with MNSCLC is carbo Abraxane better than taxol carbo?

Answer 24

Pts older than 70. OS 19.9 months vs 10.4 months

Question 25

Nsclc - solitary brains mets. Surgical resection with xrt or xrt alone?

Answer 25

Combo increases OS and QOL

Question 26

When to use pembro monotherapy in metastatic nsclc

Answer 26

PD-L1 expression >= 50% and no targetable mutations

Question 27

Keynote 024 PD-L1 > 50%. Pemb mono vs platinum. RR?

Answer 27

44.8% pemb
27.8% chemo

Question 28

Keynote 021. Carbo pem pem vs carbo pem (both with maintenance)
RR and PFS?

Answer 28

RR CPP 55% PDL1 high 80%
CP 35%
PFS 13 vs 9 months

Question 29

NCCN category 1 for metastatic squamous nsclc. 2 choices

Answer 29

Carbo taxol pemb
Carbo taxol beva and atez

Question 30

NCCN category 1 for non squamous

Answer 30

Carbo pem pem

Question 31

Best EGFR for non squamous nsclc

Answer 31

Osimertinib 80 mg po daily

Question 32

Best EML4-ALK for non squamous nsclc

Answer 32

Alectinib 600 mg po BID

Question 33

PFS for osimertinib vs erlot/gefit

Answer 33

18.9 months vs 10.2 months

Question 34

PFS for alectinib vs crizotinib

Answer 34

25.7 vs 10.4
CNS progression 12% vs 45%

Question 35

Meds for ROS-1 positive patients

Answer 35

Crizotinib 250 mg po BID
Ceritinib 450 mg po daily with food

Question 36

Treatment of BRAF V600E positive non squamous NSCLC

Answer 36

Dabrafenib 150 mg po BID and trametinib 2 mg po daily